This trial is evaluating whether Avelumab will improve 1 primary outcome and 3 secondary outcomes in patients with Tumors, Solid. Measurement will happen over the course of From enrollment to end of survival follow-up (up to 5 years after the last participant receives the last dose of avelumab).
This trial requires 161 total participants across 2 different treatment groups
This trial involves 2 different treatments. Avelumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
The following are the most frequently used treatments in patients with tumors, solid: [1. Surgery: resection (debulking), RFA: radio frequency ablation]; [2. CIMT: chemotherapy; [3. Radiotherapy: radiation therapy; 4. CCRT: chemotherapy, radiation therapy\n
The cause of most human cancers has yet to be elucidated. The tumour is a complex combination of cells that work together to develop in one place and then spread through the body. It is this tumour growth or spread that affects our health and ultimately leads to death.
Tumors, solid or neoplasms are tumours that occur within or on any or all body organ or system. Tumours form when cells grow or divide rapidly out of control. They can form as a result of normal cellular processes, but can also form abnormally as the result of a problem such as exposure to carcinogens or radiation. Tumour-forming cells normally have the ability to replicate their genomes and to divide without limit unless some form of genetic interference is present - a process known as cell 'homeostasis'. Tumours are often classified by the types of cells and structures that are affected, but, when this is not possible, by the site of occurrence.
In general terms, it has become increasingly clear that solid tumors cannot be cured. There are still many exceptions, but the cure of solid tumors in general is rare.
About 9.2 million US adults are diagnosed with cancer of the skin. As of 2006 this represented about 0.5% of all cancer cases in the Western world and about 0.6% of all cancer cases in the United Kingdom and the United States of America, making it a very common cancer.\n
The most common tumors, solid include the following: colon cancer, breast cancer, and ovarian cancer. The presence of ileosigmoid polyps is also a common finding. Other commonly detected tumors, solid include the following: carcinoid tumors, metastatic carcinomas, glomus tumors, metastatic choriocarcinomas, paragangliomas, thymoma, mediastinal germ cell tumors that mimic carcinoma, and lung cancer. The presence of gallstones or jaundice is also a common finding. Coughing up blood and difficulty swallowing are also common signs of tumors, solid.
Physicians should tailor clinical trial treatment recommendations to individual patients by considering each patient's medical evaluation, treatment history, and patient preference, as well as the clinical characteristics of the patient population in which a clinical trial will be used.
The mean age at diagnosis of primary tumors in solid non-malignant sites is 60.0 years with a standard deviation of 15.3 years. There have been two recent advances in cancer treatment that may help improve clinical outcomes for patients with solid tumors; anti-angiogenesis agents in addition to targeted therapies. However, there is still much work to be done in further examining how these new forms of treatment can improve outcomes.
We observed a higher prevalence of SLLC and its associated tumors in men. The observed male predominance of SLLC and its associated tumors is a novel finding. To our knowledge, this is the first study to report on a family-based cancer risk factor in SLLC patients. More studies are needed to elucidate the role of genetic and environmental factors in this particular manifestation of cancer. Furthermore, future studies can focus on other hereditary cancer syndromes, and SLLC patients in order to better understand the genetics of SLLC and its associated tumors.
The safety and efficacy of avelumab are confirmed. Although no statistically significant difference was detected in median time to response between avelumab- and a placebo-treated patients, avelumab may be significantly more effective compared to placebo as measured as time to response. Avelumab may induce faster responses in patients than placebo, and it may be more effective compared to placebo when patients may have been enrolled in the study in terms of an early clinical response rather than later progression of disease.
This information is important because we cannot diagnose a tumor in only one clinic. For example, the commonest cause of cancer in the pancreas is pancreatic cancer.
This phase III trial is the first to examine the safety of avelumab in combination with pembrolizumab in adults with metastatic solid tumors or cancers with PD-L1 expression, and the safety of avelumab in people with solid tumours, including metastatic cancers. summary: In a recent study, findings is evaluating whether avelumab is safe and effective for people with metastatic cancer.